Topoisomerase I inhibitors: The relevance of prolonged exposure for present clinical development

British Journal of Cancer

Volumn 76, Issue 7, 1997, Pages 952-962

  Gerrits, C J H ^a   De Jonge, M J A ^a   Schellens, J H M ^a   Stoter, G ^a   Verweij, J ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

Camptothecin; Prolonged exposure; Topoisomerase I

Indexed keywords

9 AMINOCAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; DNA TOPOISOMERASE INHIBITOR; IRINOTECAN; LURTOTECAN; TOPOTECAN;

ALOPECIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CANCER; CANCER CHEMOTHERAPY; CELL CYCLE S PHASE; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DNA STRAND BREAKAGE; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DYSPEPSIA; DYSURIA; FATIGUE; HEMATURIA; HEMORRHAGIC CYSTITIS; HUMAN; HUMAN TISSUE; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA L 1210; LEUKOPENIA; MAJOR CLINICAL STUDY; MOUSE; NAUSEA; NEUTROPENIA; NONHUMAN; ORAL DRUG ADMINISTRATION; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

EID: 0030752757     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.491     Document Type: Article

References (136)

1. Abbrazzese JL, Madden T, Schmidt S, Eaton G and Raber MN (1993) Phase I trial of topotecan (TT) administered by 24-hour infusion without and with G-CSF (abstract 1957). Proc Am Assoc Cancer Res 34: 329
2. Aller P, Rius C, Mata F, Zorilla A, Carbanas C, Bellon T and Bernabeu C (1992) Camptothecin induces differentiation and stimulates the expression of differentiation-related genes in U-937 human promonocytic leukemia cells. Cancer Res 52: 1245-1251
3. Andoh T, Ischii K, Suzuki Y, Ikegami Y, Kusunoki Y, Takemoto Y and Okada K (1987) Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I. Proc Natl Acad Sci USA 84: 5565-5569
4. Aogi K, Nishiyama M, Hirabayashi N, Toge T, Okada K, Kusano T and Ando T (1994) Establishment of a new multidrug-resistant cell line induced by continuous exposure to CPT-11. Proc Am Assoc Cancer Res 35: 451
5. Armstrong D, Rowinsky E, Donehower R, Rosenshein N, Walczak J and McGuire W (1995) A phase II trial of topotecan as salvage therapy in epithelial ovarian cancer (Abstract 769). Proc Am Soc Clin Oncol 14: 275
6. Blaney SM, Balis FM, Cole DE, Craig C, Reid JM, Ames MM, Krailo M, Reaman G, Hammond D and Poplack DG (1993). Pediatric phase I trial and pharmacokinetic study of Topotecan administered as a 24-hour continuous infusion. Cancer Res 53: 1032-1036
7. ten Bokkel Huinink WW, Rodenhuis S, Beijnen J, Dubblelman R and Koier I (1992). Phase I study of the topoisomerase I inhibitor topotecan (SK & F 104864-A) (abstract 260). Proc Am Soc Clin Oncol 11: 110
8. Burris HA, Awada A, Kuhn JG, Eckardt JR, Cobb PW, Rinaldi DA, Fields S, Smith L and Von Hoff DD (1994) Phase I and pharmacokinetic studies of topotecan administered as a 72 or 120 h continuous infusion. Anti-Cancer Drugs 5: 394-402
9. D'Arpa P, Beardmore C and Liu LF (1980) Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. Cancer Res 50: 6919-6924
10. D'Arpa P and Liu LF (1989) Topoisomerase-targeting antitumor drugs. Biochem Biophys Acta 989: 163-177
11. Del Bino G and Darzynkiewicz Z (1991) Camptothecin, teniposide, or 4′- (9-acridinylamino)-3-methanesulfon-m-anisidide, but not mitoxantrone or doxorubicine induces degradation of nuclear DNA in the S phase of HI-60 cells. Cancer Res 51: 1165-1169
12. Bowman LC, Stewart CF, Zamboni WC, Crom WR, Luo X, Heideman R, Houghton PJ, Meyer WH and Pratt CB (1996) Toxicity and pharmacodynamics of oral topotecan in pediatric patients with relapsed solid tumors. Proc Am Soc Clin Oncol 15: 462
13. 1 phase of the cell cycle and in DNA replication. J Cell Physiol 151: 478-486
14. Burris HA, Hanauske AR, Johnson RK, Mashall MH, Kuhn JG, Hilsenbeck SG and van Hoff DD (1992) Activity of topotecan, a new topoisomerase I inhibitor against human tumor colony forming units in vitro. J Natl Cancer Inst 23: 1816-1820
15. Carmichael J, Gordon A, Malfetano J, Gore M, Spaczynski M, Davidson N, Savage J, Clarke Pearson D, Hudson I, Broom C and Ten Bokkel Huinink W (1996) Topotecan, a new active drug vs paclitaxel in advanced epithelial ovarian carcinoma: international topotecan study group trial. Proc Am Soc Clin Oncol 15: 283
16. Catimel G, Chabot GG, Guastalla JP, Dumortier A, Cote C, Engel C, Gouyette A, Mathieu-Boue A, Mahjoubi M and Clavel M (1995) Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors. Ann Oncol 6: 133-140
17. Champoux J (1976) Evidence for an intermediate with a single-strand Break in the reaction catalyzed by the DNA untwisting enzyme. Proc Natl Acad Sci USA 73: 3488-3491
18. Chen AY, Yu C, Potmesil M, Wall ME, Wani MC and Liu LF (1991) Camptothecin overcomes MDR-1 mediated resistance in human carcinoma cells. Cancer Res 51: 6039-6044
19. Chou S, Kaneko M, Nakaya K and Nakamura Y (1990) Induction of differentiation of human and mouse myeloid leukemia cells by camptothecin. Biochem Biophys Res Commun 166: 160-167
20. Covey JM, Jaxel C, Kohn KW and Pommier Y (1989) Protein linked DNA strand breaks induced in mammalian cells by camptothecin an inhibitor of topoisomerase I. Cancer Res 49: 5016-5022
21. Creaven PJ, Allen LM and Muggia FM (1972) Plasma camptothecin (NSC 100880) levels during a 5 days course of treatment: relation to dose and toxicity. Cancer Chemother Rep 56: 573-578
22. Creemers GJ, Bolis G, Gone M, Scarfone G, Lacave AJ, Guastalla JP, Despos R, Favelli G, Kreinberg R, Van Belle S, Hudson I, Verweij J and Ten Bokkel Huinink WW (1996) Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer. results of a large European phase II study. J Clin Oncol 14: 3056-3061
23. Dahut W, Harold N, Takimoto C, Allegra C, Chen A, Hamilton M, Arbuck S, Sorensen M, Grollman F, Nakashina H, Lieberman R, Liang M, Corse W and Corem J (1996) Phase I and pharmacologic study of 9-aminocamptothecin given by 72-hour infusion in adult cancer patients. J Clin Oncol 14: 1236-1244
24. Daoud SS, Fetouh MI and Giovanella BC (1995) Antitumor effect of liposome-incorporated camptothecin in human malignant xenografts. Anticancer Drugs 6: 83-93
25. Drengler R, Burris H, Dietz A, Eckhardt J, Eckhardt G, Hodges S, Kraynak M, Kuhn J, Peacock N, Rinaldi D, Rizzo J, Rodriguez G, Schaaf L, Smith L, Thurman A and Von Hoff D (1996) A phase I trial to evaluate orally administered Irinotecan HCI (CPT-11) given daily × 5 every 3 weeks in patients with refractory malignancies. Proc Am Soc Clin Oncol 15: 489
26. Drewinko B, Freireich EJ and Gottlieb JA (1974) Lethal activity of camptothecin sodium on human lymphoma cells. Cancer Res 34: 747-750
27. Eckardt JR, Rodriguez GI, Burris HA, Wissel PS, Fields SM, Rothenberg ML, Smith L, Thurman A, Kunka RL, De Pee SP, Littlefield D, White LJ and Von Hoff DD (1995) A Phase I and pharmacokinetic study of the topoisomerase I inhibitor GG211. Abstract 1544. Proc Am Soc Clin Oncol 14: 476
28. O'Dwyer P, Cassidy J, Kunka R, Pagarez L, Kaye S, De Pee S, Littlefield D, De Maria D, Selinger K, Beranke P, Collis P and Wissel P (1995) Phase I trial of GG211, a new topoisomerase inhibitor using a 72 hour continuous infusion (CI). Proc Am Soc Clin Oncol 14: 471
29. Emerson L, Mcintyre G, Luzzio M and Wissel PS (1994) Preclinical antitumor activity of a novel water-soluble camptothecin analog (GI147122 c). Ann Oncol 5 (suppl. 5): 185
30. Emerson DL, Besterman JM, Braun R, Evans MG, Leitner PP, Luzzio MJ, Shaffer JE, Sternbach DD, Uehling D and Vuong A (1995) In vivo antitumor activity of two new seven substituted water-soluble camptothecin analogues. Cancer Res 55: 603-609
31. Eng WK, Faucette L, Johnson RK and Stenglanz R (1989) Evidence that DNA topoisomerase is necessary for the cytotoxic effects of campotothecin. Mol Pharmacol 34: 755-760
32. Furman WL, Balur SD, Pratt CB, Rivera GK, Evans WE and Stewart CF (1996) Escalating systemic exposure of continuous infusion Topotecan in children with recurrent acute leukemia. J Clin Oncol 14: 1404-1511
33. Gerrits CJH, Creemers GJ, Schellens JHM, Wissel PS, Planting AST, Kunka R, Selinger K, De Boer-Dennert M, Marijnen Y, Harteveld M and Verweij J (1996) Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily ×5 intravenous administration. Br J Cancer 73: 744-750
34. Giovanella BC, Stehlin JS, Wall ME, Wani MC, Nicholas AW, Liu LF, Silber R and Potmesil M (1989) DNA-topoisomerase I-targeted chemotherapy of human colon cancer in Xenografts. Science 246: 1046- 1048
35. Giovanella BC, Hinz HR, Kozielski AJ, Stehlin JS, Silber R and Potmesil M (1991) Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20-(S)-camptothecin. Cancer Res 51: 3052-3055
36. Giovanella BC, Stehlin JS, Hinz HR, Vardeman D, Mendoza JT and Potmesil M (1994) Studies of time/dose intensity in treatment of human cancer xenografts with camptothecin analogues (abstract 2713). Proc Am Assoc Cancer Res 35: 455.
37. Gottlieb JA and Luce JK (1972) Treatment of malignant melanoma with camptothecin (NSC 100880). Cancer Chemother Resp 56: 103-105
38. Gottlieb JA, Guarino AM, Call JB, Oliverio VT and Block JB (1970) Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC 100880). Cancer Chemother Rep 54: 461-470
39. Guarino AM, Anderson JB and Starkweather DK (1973) Pharmacologic studies of camptothecin (NSC-100880): distribution, plasma protein binding and biliary excretion. Cancer Chemother Rep 57: 125-140
40. Gupta RS, Gupta R, Eng B, Lock RB, Ross WE, Hertzberg RP, Caranfa MJ and Johnson RK (1988) Camptothecin-resistant mutants of Chinese hamster ovary cells containing a resistant form of topoisomerase I. Cancer Res 48: 6404-6410
41. Haas NB, LaCreta FP, Walczak J, Hudes GR, Brennan JM, Ozois RF and O'Dwyer PJ (1994) Phase I/Pharmacokinetic study of topotecan by 24 hour continuous infusion weekly. Cancer Res 54: 1220-1226
42. Hendricks CB, Rowinsky EK, Grochow LD, Donehower RC and Kaufmann SH (1992) Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864) a new camptothecin analogue. Cancer Res 52: 2268-2278
43. Hinz HR, Harris NJ, Natelson EA and Giovanella BC (1994) Pharmacokinetics of the in vivo and in vitro conversion of 9-nitro-20-(S)-camptothecin to 9-amino-20-(S)-camptothecin in humans, dogs and mice. Cancer Res 54: 3096-3100
44. Hochster H, Liebes L, Speyer J, Sorich J, Taubes B, Oratz R, Wernz J, Chachoua A, Raphael B, Vinci RZ and Blim RH (1994) Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen. J Clin Oncol 12: 553-559
45. Hochster H, Potmesil M, Liebs L, Sorich J, Taubes B, Dewey D, Oratz R, Chachoua A and Speyer J (1996a) A phase I study of 9-amino-camptothecin (9AC) by prolonged infusion over 21 days. NCI-EORTC 9th Symposium on New Drugs in Cancer Therapy. p. 130, Amsterdam
46. Hochster H, Speyer J, Wadler S, Runowicz C, Wallach R, Oratz R, Chacoua A, Sorich J, Taubes B, Ludwig E, Broom C and Blum R (1996b) Phase II study of topotecan 21 day infusion in platinum-treated ovarian cancer: a highly active regimen. Proc Am Soc Clin Oncol 15: 285
47. Horwitz SB (1974) Novel inhibitors of RNA synthesis. Fed Proc 33: 2281-2287
48. Horwitz SB and Horwitz MS (1973) Effects on Camptothecin on the breakage and repair of DNA during the cell cycle. Cancer Res 33: 2834-2836
49. Horwitz SB, Chang CK and Grollman AP (1971) Studies on camptothecin I. Mol Pharmacol 7: 632-644
50. Houghton PJ, Chesire PJ, Myer L, Stewart CF, Synold TW and Houghton JA (1991) Evaluation of 9-dimethylaminomethyl-10-hydroxy-camptothecin (topotecan) against xenografts derived from adult and childhood tumors. Cancer Chemother Pharmacol 31: 229-239
51. Houghton PJ, Cheshire PJ, Hallman JD, Bissery MC, Mathieu-Boue A and Houghton HA (1993) Therapeutic efficacy of topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino-]-1 piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9- dimethylaminomethyl-10-hydroxy-camptothecin. Cancer Res 53: 2823-2829
52. Houghton PJ, Chesire PJ, Hallman JD, Lutz L, Friedman HS, Danks MK and Houghton JA (1995) Efficacy of topoisomerase I inhibitor topotecan and irinotecan administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 36: 393-403
53. Hsiang YH and Liu LF (1988) Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 48: 1722-1726
54. Hsiang YH, Likan MG and Liu LF (1989) Arrest of replication forks by drug stabilized topoisomerase-I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 49: 5077-5082
55. Hwang JL, Shyy SH, Chen AY, Juan CC and Whang-Peng J (1989) Studies of topoisomerase specific antitumor drugs in human lymphocytes using rabbit antisera against recombinant human topoisomerase II polypeptide. Cancer Res 49: 958-962
56. Hwong CL, Chen MS and Hwang J (1989) Phorbol ester transiently increases topoisomerase I mRNA levels in human skin fibroblasts. J Biol Chem 264: 14923-14926
57. Hwong CL, Chen CY, Shang HF and Hwang J (1993) Increased synthesis and degradation of DNA topoisomerase I during the initial phase of human T-lymphocyte proliferation. J Biol Chem 268: 18982-18986
58. Ilson D, Motzer RJ, O'Moore P, Nanus D and Bosl GJ (1993) A phase II trial of topotecan in advanced renal cell carcinoma. Proc Am Soc Clin Oncol 12: 248
59. Jaxel CJ, Kohn KW, Wani MC, Wall ME and Pommier Y (1989) Structure activity study of the action of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity. Cancer Res 49: 1465-1469
60. Juan C, Hwang J, Liu A, Whang-Peng J, Knutsen T, Huebner K, Croce C, Zhang H, Wang J and Liu L (1988) Human DNA topoisomerase I is encoded by a single copy gene that maps to chromosome region 20q12-13.2. Proc Natl Acad Sci USA 85: 8910-8913
61. Kantarjian HM, Beran M, Ellis A, Zwelling L, O'Brien S, Cazenave L, Koller C, Rios MB, Plunkelt W, Keatin M and Estey EM (1993) Phase I study of Topotecan, a new topoisomerase I inhibitor in patients with refractory or relapsed acute leukemia. Blood 81: 1145-1151
62. Kanzawa F, Sugimoto Y, Minato K, Kasahara K, Bungo M, Nakagawa K, Fujiwara Y, Liu LF and Saijo N (1990) Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: characterization and mechanism of resistance. Cancer Res 50: 5919-5924
63. Kanzawa F, Kondoh H, Kwan S and Saijo N (1993) Role of carboxyl esterase on metabolism of camptothecin analog (CPT-11) in non-small cell lung cancer cell line PC-7 cells. Proc Am Assoc Cancer Res 33: 427
64. Kaufmann SH (1989) Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs. A cautionary note. Cancer Res 49: 5870-5878
65. Kawato Y, Aonuma M, Hirota Y, Kuga H and Sato K (1991) Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 51: 4187-4191
66. Kessel D (1971) Effects of camptothecin on RNA synthesis in leukemia L 1210 cells. Biochem Biophys Acta 246: 225-232
67. Kharbanda S, Rubin E, Gunji H, Hinz H, Giovanella B, Pantazis P and Dufe D (1991) Camptothecin and its derivatives induce expression of the c-jun protooncogene in human myeloid leukemia cells. Cancer Res 51: 6636-6642
68. Khater C, Yao KS, Green FJ Halbherr T, Raskay B, Scher R and O'Dwyer PJ (1995) Interindividual variation in topoisomerase I expression and lopotecan toxicity (abstrat 2687). Proc Am Assoc Cancer Res 36: 450
69. Khater C, Twelves C, Grochow L, De Maria D, Paz-Ares L, Littlefield D, Prittchard JF, Wissel P, Kaye S and O'Dwyer PJ (1996) Phase I trial of the topisomerase I inhibitor GG211 as a 21 day continuous infusion. Proc Am Soc Clin Oncol 15: 483
70. Kjeldsen E, Bonven BJ, Andoh T, Ischii K, Okada K, Bolund L and Westergaard O (1988) Characterization of a camptothecin-resistant human DNA topoisomerase I. J Biol Chem 263: 3912-3916
71. Kraut EH, Stanbus A, Mayernich D, King G and Balcerzak SD (1995) Phase II trial of topotecan in metastatic malignant melanoma. Proc Am Assoc Cancer Res 36: 238
72. Kudelka A, Edwards C, Freedman R, Wallin B, Hord M, Howell E, Harper K, Raber M and Kavanagh J (1993) An open phase II study to evaluate the efficacy and toxicity of topotecan administered intravenously as 5 daily infusions every 21 days to women with advanced epithelial ovarian carcinoma (abstract 821) Proc Am Soc Clin Oncol 12: 259
73. Kuhn J, Dizzo J, Eckardt J, Fields S, Cobb P, Rodriguez G, Rinadi D, Drendgler R, Smith L, Peacock N, Thurman A, Delacruz P, Hodges S, Von Hoff D and Burris H (1995) Phase I bioavailability study of oral topotecan (abstract 1538). Proc Am Soc Clin Oncol 14: 474
74. Langevin AM, Casto DT, Kuhn JG, Thomas PJ and Vietti T (1996) A phase I trial of 9-amino-camptothecin in children with refractory solid tumors. A pediatric oncology group study. NCI-EORTC 9th symposium on new drugs in cancer therapy. 130
75. Ling YH, Tseng MT and Nelson JA (1991) Differentiation induction of human promyelocytic leukemia cells by 10-hydroxycamptothecin, a topoisomerase I inhibitor. Differentiation 46: 135-141
76. Liu LF and Miller KG (1981) Eukaryotic DNA topoisomerases: two forms of type I DNA topoisomerases from HeLa cell nuclei. Proc Natl Acad Sci USA 78: 3487-3491
77. Liu LF and D'Arpa P (1992) Topoisomerase-targeting antitumor drugs: mechanisms of cytotoxicity and resistance. Important Adv Oncol 442: 79-89
78. Lynch TJ, Kalish L, Strauss G, Elias A, Skariv A, Schulman LN, Posner M and Frei H (1994) Phase II study of topotecan in metastatic non-small cell lung cancer. J Clin Oncol 12: 347-352
79. Ma J, Maliepaard M, Nooter K, Loos WJ, Kolker HJ, Verweij J, Stoter G and Schellens JHM (1996) Reduced cellular accumulation of topotecan, a novel mechanism of resistance in a human ovarian cancer cell line (to be submitted)
80. Malmstrom H, Sorbe B and Simonsen E (1996) The effect of topotecan in platinum refractory ovarian cancer. Proc Am Soc Clin Oncol 15: 299
81. Moertel CCG, Schutt AJ, Reitemeier RJ and Hatin RG (1972) Phase II study of camptothecin (NSC 100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep 56: 95-101
82. Muggia FM, Creaven PJ, Hansen HH, Cohen MH and Selanrig OS (1972) Phase I clinical trial of weekly and daily treatment with camptothecin (NSC 100880): correlation with preclinical studies. Cancer Chemother Rep 56: 515-521
83. Nakai H, Fukuoka M, Furuse K, Nakao I, Yoshimoni K, Ogura T, Hara N, Sakata Y, Saito H and Hasegawa K (1991) An early phase II study of CPT-11 for primary lung cancer. Jpn Cancer Chemother 18: 607-612
84. Negoro S, Fukuoka M, Nitani H, Suzuki A, Nakabyashi T, Kimuru M, Motomiya M, Kupita Y, Hasegawa K and Kuriyama T (1991) An early phase II study of CPT-11, a camptothecin derivative, in patients with primary lung cancer. Jpn J Cancer Chemother 18: 1013-1019
85. Nitiss J and Wang JC (1988) DNA topoisomerase-targeting antitumor drugs can be studied in yeast. Proc Natl Acad Sci USA 85: 7501-7505
86. Noda K, Sasaki H, Yamamoto K, Yamamoto T, Hishimura R, Sugiyama T and Nakajama H (1996) Phase II trial of topotecan for cervical cancer of the uterus. Proc Am Soc Clin Oncol 15: 280
87. Ohe Y, Sasaki Y, Sinkai T, Eguchi K, Tamura T, Kojima A, Kunikane H, Okamoto H, Karato A, Ohmatsu H, Kanzawa F and Saijo N (1992) Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion. J Natl Cancer Inst 84: 972-974
88. Ohno R, Okada K, Masaoka T, Kuramoto A, Arima T, Yoshida Y, Ariyoshi H, Ichimaru M, Sakai Y, Oguro M, Iti Y, Morishima Y, Yokomaku S and Ota K (1990) An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma. J Clin Oncol 8: 1907-1912
89. Pantazis P, Hinz HR, Mendoza JT, Kozielski AJ, Williams LJ, Stehlin JS and Giovanella BC (1992) Complete inhibition of growth followed by death of human malignant xenografts in immunodeficient mice induced by camptothecins. Cancer Res 52: 3980-3987
90. Pantazis P, Early JA, Kozielski AJ, Mendoza JT, Hinz HR and Glovanella BC (1993a) Regression of human breast carcinoma tumors in immunodeficient mice treated with 9-nitro-camptothecin: differential response of nontumorigenic and tumorigenic human breast cancer cells in vitro. Cancer Res 53: 1577-1582
91. Pantazis P, Kozielski AJ, Vardeman DM, Petry ER and Giovanella BC (1993b) Efficacy of camptothecin congeners in the treatment of human breast carcinoma xenografts. Oncol Res 5: 273-281
92. Pantazis P, Kozielski AJ, Mendoza JT, Early JA, Hinz HR and Giovanella BC (1993c) Camptothecin derivatives induce regression of human ovarian carcinomas grown in nude mice and distinguish between non tumorigenic and tumorigenic cells in vitro. Int J Cancer 53: 863-871
93. Pantazis P, Harris N, Mendoza J and Giovanella B (1994a) Conversion of 9-nitrocamptothecin to 9-amino-camptothecin by human blood cells in vitro. Eur J Hematol 53: 246-248
94. Pantazis P, Kozielski A, Rodriguez R, Petry E, Wani M, Wall M and Giovanella B (1994b) Therapeutic efficacy of camptothecin derivatives against human melanoma xenografts. Melanoma Res 4: 5-10
95. Perez-Soler R, Fossella FV, Glisson BS, Lee JS, Murphy WK, Shin DM, Kemp BL, Lee JJ, Kane J, Robinson RA, Lippman SM, Kurie JM, Huher MH, Raber MN and Hong WK (1996) Phase II study of topotecan in patients with advanced non-small cell lung cancer (NSCLC) previously untreated with chemotherapy J Clin Oncol 14: 503-513
96. Phillips PC, Janss A, Kaufmann SH, Levow C, Yao Y and Colvin OM (1994) Topoisomerase I inhibitor schedule dependent activity and determinants of cytotoxicity in human brain tumors cell lines (abstract 2161). Proc Am Assoc Cancer Res 35: 363
97. Plaxe S, Christen R, O'Quigley J, Braly P, Freddo J, McClay E, Heath D and Howell S (1993) Phase I trial of intra-peritoneal Topotecan (abstract 360). Proc Am Soc Clin Oncol 12: 140
98. Potmesil M, Liebes L, Drygas J, Sehiya S, Morse L, Kozielski AJ, Wall ME, Wani MC, Stehlin JS and Giovanella BC (1995) Pharmacodynamics/pharmacokinetics of intragastric (IG) camptothecin analogs in a human cancer xenograft model (abstract 2652). Proc Am Assoc Cancer Res 36: 445
99. Pratt CB, Steward C, Santana VM, Bowman L, Furman W, Ochs J, Marina N, Kuttesch JF, Heideman R, Sandlund J, Avery L and Meijer WH (1994) Phase I study of topotecan for pediatric patients with malignant solid tumors. J Clin Oncol 12: 539-543
100. Puc HS, Bajorin DF, Bosl GJ, Amsterdam A and Motzer RJ (1995) Phase II trial of topotecan in patients with cisplatin-refractory germ cell tumors. Investig New Drugs 13: 163-165
101. Recondo G, Abbruzzese J, Newman B, Newman R, Kuhn J, Von Hoff D, Garteiz D and Raber M (1991). A phase I trial of topotecan (TOPO) administered by a 24-hour infusion (abstract 1229). Proc Assoc Cancer Res 34: 206
102. Reid JM, Burch PA, Benson LM, Gilbert JA, Richardson RL and Ames M (1992) Phase I clinical and pharmacologic evaluation of topotecan administered by a 24-hour continuous infusion (abstract 1553). Proc Am Assoc Cancer Res 33: 259 Robert F, Wheeler RH, Molthrop DC, Greene P and Chen S (1994) Phase II study of topotecan in advanced head and neck cancer: identification of an active new agent (abstract 905). Proc Am Soc Clin Oncol 13: 281
103. Reid JM, Burch PA, Benson LM, Gilbert JA, Richardson RL and Ames M (1992) Phase I clinical and pharmacologic evaluation of topotecan administered by a 24-hour continuous infusion (abstract 1553). Proc Am Assoc Cancer Res 33: 259 Robert F, Wheeler RH, Molthrop DC, Greene P and Chen S (1994) Phase II study of topotecan in advanced head and neck cancer: identification of an active new agent (abstract 905). Proc Am Soc Clin Oncol 13: 281
104. Roca J (1995) The mechanisms of DNA topoisomerases. Trends Biochem Sci 156-160
105. Roethke S, Ozols RF and Hudes GR (1993) Phase II study of topotecan for hormone refractory prostate cancer (HRPC). Proc Am Soc Clin Oncol 12: 247
106. Rothenberg ML, Rinaldi DA, Smith LS, Schaaf LJ, Hodges S, Thurman AM, Ichhpurani NK, Eckardt SG, Rodriguez GI, Villabona M, Drengle RR, Dietz AJ, Murphy TC, Burris MA and Von Mopp DD (1996) Every other week Trinotecan (CPT-II): Results of a phase I and pharmacokinetic (PK) study. Proc Am Soc Clin Oncol 15 (abstract 1561)
107. Rowinsky EK, Growchow LB, Hendricks CB, Ettinger DS, Forastiere AA, Hurowitz LA, McGuire WP, Sartorius SE, Lubejko BG, Kaufman SH and Donehower RC (1992) Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. J Clin Oncol 10: 647-656
108. Rubin E, Wood V, Bahrti A, Trites D, Lynch C and Kufe D (1994) A phase I trial of 9-amino-camptothecin (9AC) (abstract 1465). Proc Am Assoc Cancer Res 35: 25
109. Sabiers JH, Berger NA, Berger SJ, Haaga JR, Hoppel CL and Wilson JKV (1993) Phase I trial of topotecan administration as a 72 hour infusion. Proc Am Soc Cancer Res 34: 426
110. Saijo N, Nishio K, Kubota N, Kanzawa F, Shinkai T, Karato A, Ssaki Y, Eguchi K, Tamura T, Ohe Y, Oshita F and Nishio M (1994) 7-ethyl-10-[4-(1-piperidono)-1-piperidino] carbonyloxy camptothecin: mechanism of resistance and clinical trials. Cancer Chemother Pharmacol 34 (suppl.): 112-117
111. Saltz L, Sirott M, Young C, Tang W, Niedzweicki D, Tzy-Jyun Y, Tao Y, Trochanowski B, Wright P, Barbosa B, Toomasi F and Kelsen D (1992) Phase I and clinical pharmacologic study of intravenous topotecan alone and with granulocyte colony stimulating factor (G-CSF). Ann Oncol 3 (suppl. 1): 84
112. Samuels DS and Shimizu N (1992) DNA topoisomerase I phosphorylation in murine fibroblasts treated with 12-O-tetradecanoylphorbol-13 acetate and in vitro by protein kinase C. J Biol Chem 267: 11156-11162
113. Schaeppi U, Fleischman RW and Cooney DA (1974) Toxicity of camptothecin (NSC-100880). Cancer Chemother Rep 5: 25-36
114. Schellens JHM, Creemers GJ, Beynen JH, Rosing H, McDonald M, Davies B and Verweij J (1996) Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor. Br J Cancer 73: 1268-1271
115. Schiller JH, Kim K and Johnson D (1994) Phase II study of topotecan in extensive stage small cell lung cancer. Proc Am Soc Clin Oncol 13: 330
116. McSheehy PM, Gervasoni M, Lampasona V, Erba E and D'Incalci M (1991) Studies of the differentiation properties of camptothecin in human leukemia cells K562. Eur J Cancer 27: 1406-1411
117. Smith RE, Lew D, Rodriguez GI, Taylos SA and Schuller D (1996) Evaluation of topotecan in recurrent or metastatic head and neck cancer. Proc Am Soc Clin Oncol 15: 310
118. Stehlin JS, Natelson EA, Hinz HR, Giovanella BC, Ipolyi PD, Fehin KM, Trezona TP, Vardeman DM, Harris NJ, Marcee AK, Kozielski AJ and Ruiz-Razura A (1995) Phase I clinical trial and pharmacokinetic results with oral administration of 20-(S)-camptothecin. In Campothecins: New Anticancer Agents, Potmesil M and Pinedo H. (ed.), pp. 59-65. CRC Press: Boca Raton
119. Stewart AF and Schutz G (1987) Camptothecin-induced in vivo Topoisomerase I devagesin the transcriptionally active tyrosine aminotransferase gene. Cell 50: 1109-1117
120. Subramanian D, Kraut E, Staubus A, Young DC and Muller MT (1995) Analysis of topoisomerase I/DNA complexes in patients administered topotecan. Cancer Res 55: 2097-2103
121. Sugarman SM, Agani JA, Daugherty K, Winn R, Lanzotti V, Bearden JD and Abbruzzese JL (1994) A phase II trial of topotecan (TPT) for the treatment of advanced measurable colorectal cancer (abstract 686). Proc Am Soc Clin Oncol 13: 225
122. Sugimoto Y, Tsukahara S, Oh-Hara T, Isoe T and Tsuruo T (1990) Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody. Cancer Res 50: 6925-6930
123. Takeda S, Shimazoe T, Sato K, Sigimoto Y, Tsurno T and Kono A (1992) Differential expression of DNA topoisomerase I gene between CPT-11 acquired- and native resistant human pancreatic tumor cell lines: detected by RNA/PCR based quantitation assay. Biochem Biophys Res Commun 184: 618-625
124. Takeuchi S, Dobashi K, Fujimoto S, Tanaka K, Suzuki M, Terashima Y, Hasumi K, Akiya K, Negishi Y and Tamay T (1991a) A late phase II study of CPT-11 on uterine cervical cancer and ovarian cancer. Jpn J Cancer Chemother 18: 1681-1689
125. Takeuchi S, Takamizawa H, Takeda Y, Ohkawa T, Tamaya T, Noda K, Sugawa T, Sekiba K, Yakushiji M and Taguchi T (1991b) An early phase II study of CTP-11 for gynecologic cancers. Jpn J Cancer Chemother 18: 579-584
126. Takimoto CH, Klecker RW, Dahut WL, Brillhart N, Yee LK, Strong JM, Nakashima H. Lieberman R, Allegra CJ and Grem JL (1994) Preliminary pharmacokinetics of the active lactone form of 9-aminocamptothecin using a sensitive new HPL assay. Proc Am Assoc Cancer Res 35: 242
127. Takimoto CH, Dahut W, Harold N, Morrison GB, Quinn MF, Callen E, Liang MD, Arbuck SG, Chen A, Hamilton JM, Allegra CJ, Sorensen JM and Grem JL (1996) A phase I trial of a prolonged infusion of 9-amino-camptothecin (9AC) in adult patients with solid tumors. Proc Am Soc Clin Oncol 15: 488
128. Tanizawa A and Pommier Y (1992) Topoisomerase I alteration in a camptothecin-resistant cell line derived from Chinese hamster DC3F cells in culture. Cancer Res 52: 1849-1854
129. Tsuda H, Takatsuki K, Ohno R, Masaoko T, Okada K, Shirakawa S, Ohashi Y, Ohta K and Taguchi T (1992) A late phase II trial of a potent topoisomerase I inhibitor, CPT-11, in malignant lymphoma. Proc Am Soc Clin Oncol 11: 316
130. Venditti JM (1971) Treatment schedule dependency of experimentally active antileukemic (L1210) drugs. Cancer Chemother Rep 2: 35-59
131. Verschraegen CF, Natelson E, Giovanella B, Kavanagh JJ, Freedman RS, Kudelka AP, Edwards CL and Stehlin J (1996) Phase I study of oral 9-nitro-camptothecin. Proc Am Soc Clin Oncol 15: 482
132. Verweij J, Lund B, Beynen J, Planting A, De Boer-Dennert M, Koier I, Rosing H and Hansen H (1993) Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor. Ann Oncol 4: 673-678
133. Wall ME, Wani MC, Cook CE, Palmer KH, McPhail AT and Lim GA (1966) Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloid leukemia and tumor inhibitor from camptotheca acuminata. J Am Chem Soc 88: 3888-3890
134. Wanders J, Ardizanni A, Hansen HH, Dombernowsky P, Postmus PE, Buitenhuis M, McDonald M, Giaccone G and Verweij J (1995) Phase II study of topotecan in refractory and sensitive small cell lung cancer (SCLC) (abstract 1415). Proc Am Assoc Cancer Res 36: 237
135. Wanders J, Ten Bokkel Huinink WW, Heinrich B, Gore M, Calvert AH, Lehnert M, Ten Velde A and Verweij J (1996) Phase II studies vvith GI147211 in 5 different tumor types. Preliminary results. NCI-EORTC symposium on new drugs in cancer therapy. Amsterdam, March, p. 131
136. Zhang H, Wang JC and Liu LF (1988) Involvement of DNA topoisomerase I in transcription of human ribosomal RNA genes. Proc Natl Acad Sci USA 85: 1060-1064